Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Personalis, Inc.PSNL · Entity 4572 | Director | May 12, 2026 | May 14, 2026 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Personalis, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,250 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 6,250 · Balance 6,250 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2036-05-12 | Direct | 37,500 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 37,500 · Balance 37,500 F2: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control.
F2: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control.
QuidelOrtho Corp
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 15,532 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. |
| Restricted Stock Units (Converted)SEC Table II · derivative / convertible security | Direct | 6,656 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 6,656 · Balance 6,656 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4: 1,664 shares vested on June 25, 2026, 1,664 shares will vest on September 25, 2026, 1,664 shares will vest on December 25, 2026, and 1,664 shares will vest on March 25, 2027. |
| Restricted Stock Units (Premium)SEC Table II · derivative / convertible security | Direct | 1,997 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Grant · Acquired 1,997 · Balance 1,997 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: The restricted stock units will vest on June 25, 2027.
F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
F4: 1,664 shares vested on June 25, 2026, 1,664 shares will vest on September 25, 2026, 1,664 shares will vest on December 25, 2026, and 1,664 shares will vest on March 25, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Evoke Pharma Inc
Report date December 17, 2025 · Filed December 17, 2025
Section 16 reporting ended · disclosed 2025-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.41 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-17 · Disposition to issuer · Disposed 1,187 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-17 · Disposition to issuer · Disposed 5,833 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-17 · Disposition to issuer · Disposed 1,187 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
QUIDEL CORP /DE/
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 18,684 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $27.91 · Expires 2024-11-17 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 7,021 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $15.74 · Expires 2026-05-17 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 7,021 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $24.80 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-27 · Disposition to issuer · Disposed 5,065 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-27 · Disposition to issuer · Disposed 1,050 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-27 · Disposition to issuer · Disposed 315 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-27 · Disposition to issuer · Disposed 328 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-27 · Disposition to issuer · Disposed 98 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-27 · Disposition to issuer · Disposed 512 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-05-27 · Disposition to issuer · Disposed 153 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F3: Vested in full.
F4: Each restricted stock unit represents the right to receive one share of Quidel common stock.
F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2023 Filed May 16, 2023 22:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029934 · doc4.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,049 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 14, 2023 Filed May 16, 2023 22:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029934 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,734 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:50 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-23-028799 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2033-05-09 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:21 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Premium) · Derivative | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035182 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273 Underlying: Common Stock · 273 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on June 6, 2023. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on June 6, 2023. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:21 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Converted) · Derivative | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035182 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910 Underlying: Common Stock · 910 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, June 6, 2022. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, June 6, 2022. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:21 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035182 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,248 Underlying: Common Stock · 2,248 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on June 6, 2023. F2 · derivative.expiration_date: The restricted stock units vest on June 6, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 153 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 11 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 512 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 10 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 512 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 98 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 9 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 8 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 328 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 7 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 315 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 6 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,050 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 5,065 | $0.00 Strike: $24.80 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 5 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,065 shares Expires 2027-05-16 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 7,021 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,021 shares Expires 2026-05-17 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 7,021 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,021 shares Expires 2025-05-05 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 3,333 | $0.00 Strike: $27.91 | $0.00 |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2024-11-17 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:26 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerCommon Stock | 18,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020408 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 153 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 11 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153 Underlying: Common Stock · 153 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 512 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 10 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512 Underlying: Common Stock · 512 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 98 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 9 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98 Underlying: Common Stock · 98 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 8 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328 Underlying: Common Stock · 328 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 7 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315 Underlying: Common Stock · 315 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 6 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050 Underlying: Common Stock · 1,050 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F5 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F6 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 5,065 | $0.00 Strike: $24.80 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 5 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,065 Underlying: Common Stock · 5,065 shares Expires 2027-05-16 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 7,021 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,021 Underlying: Common Stock · 7,021 shares Expires 2026-05-17 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 7,021 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,021 Underlying: Common Stock · 7,021 shares Expires 2025-05-05 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 3,333 | $0.00 Strike: $27.91 | $0.00 |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2024-11-17 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:38 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 18,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020498 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,684 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:51 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031196 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,624 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:51 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031196 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 15, 2022 Filed May 17, 2022 19:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units (Premium) · Derivative | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029874 · doc4.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.expiration_date: Restricted stock units released pursuant to the Issuer's deferred compensation plan. Read SEC document |
| May 15, 2022 Filed May 17, 2022 19:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units (Converted) · Derivative | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029874 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 791 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.expiration_date: Restricted stock units released pursuant to the Issuer's deferred compensation plan. Read SEC document |
| May 15, 2022 Filed May 17, 2022 19:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029874 · doc4.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 15, 2022 Filed May 17, 2022 19:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029874 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 23:37 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001209191-22-026083 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2032-04-26 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:43 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 153 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034715 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153 Underlying: Common Stock · 153 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 18, 2022. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 18, 2022. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:43 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 512 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034715 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512 Underlying: Common Stock · 512 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 18, 2021. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 18, 2021. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:43 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034715 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624 Underlying: Common Stock · 1,624 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 18, 2022. F2 · derivative.expiration_date: The restricted stock units vest on May 18, 2022. Read SEC document |
| May 16, 2021 Filed May 18, 2021 20:00 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units (Premium) · Derivative | 576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033798 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.expiration_date: Restricted stock units released on the transaction date pursuant to the Issuer's deferred compensation plan. Read SEC document |
| May 16, 2021 Filed May 18, 2021 20:00 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033798 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:19 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032983 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,040 shares Expires 2021-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:19 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032983 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 05, 2021 Filed Jul 23, 2021 22:30 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-21-048033 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2031-05-04 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:49 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001209191-20-032973 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2030-05-26 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:21 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030280 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. F3 · derivative.expiration_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:21 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030280 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:01 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029394 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040 Underlying: Common Stock · 1,040 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F4 · derivative.exercise_date: The restricted stock units vest on May 12, 2021. F4 · derivative.expiration_date: The restricted stock units vest on May 12, 2021. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:01 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 98 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029394 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98 Underlying: Common Stock · 98 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on May 12, 2021. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on May 12, 2021. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:01 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029394 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328 Underlying: Common Stock · 328 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 12, 2020. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 12, 2020. Read SEC document |
| May 15, 2019 Filed May 16, 2019 19:34 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030642 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.